Logo image of LQDA

LIQUIDIA CORP (LQDA) Stock Fundamental Analysis

NASDAQ:LQDA - Nasdaq - US53635D2027 - Common Stock - Currency: USD

13.55  +0.06 (+0.44%)

After market: 13.55 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LQDA. LQDA was compared to 198 industry peers in the Pharmaceuticals industry. LQDA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LQDA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LQDA had negative earnings in the past year.
LQDA had a negative operating cash flow in the past year.
LQDA had negative earnings in each of the past 5 years.
In the past 5 years LQDA always reported negative operating cash flow.
LQDA Yearly Net Income VS EBIT VS OCF VS FCFLQDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

LQDA has a Return On Assets of -56.62%. This is in the lower half of the industry: LQDA underperforms 64.14% of its industry peers.
LQDA's Return On Equity of -168.74% is on the low side compared to the rest of the industry. LQDA is outperformed by 65.15% of its industry peers.
Industry RankSector Rank
ROA -56.62%
ROE -168.74%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LQDA Yearly ROA, ROE, ROICLQDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

LQDA's Gross Margin of 58.00% is fine compared to the rest of the industry. LQDA outperforms 65.66% of its industry peers.
In the last couple of years the Gross Margin of LQDA has declined.
The Profit Margin and Operating Margin are not available for LQDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
LQDA Yearly Profit, Operating, Gross MarginsLQDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for LQDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LQDA Yearly Shares OutstandingLQDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
LQDA Yearly Total Debt VS Total AssetsLQDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 0.20, we must say that LQDA is in the distress zone and has some risk of bankruptcy.
LQDA has a Altman-Z score of 0.20. This is comparable to the rest of the industry: LQDA outperforms 58.08% of its industry peers.
A Debt/Equity ratio of 1.26 is on the high side and indicates that LQDA has dependencies on debt financing.
With a Debt to Equity ratio value of 1.26, LQDA is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Altman-Z 0.2
ROIC/WACCN/A
WACC9.63%
LQDA Yearly LT Debt VS Equity VS FCFLQDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 4.43 indicates that LQDA has no problem at all paying its short term obligations.
LQDA's Current ratio of 4.43 is fine compared to the rest of the industry. LQDA outperforms 67.68% of its industry peers.
A Quick Ratio of 4.42 indicates that LQDA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.42, LQDA is doing good in the industry, outperforming 69.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.43
Quick Ratio 4.42
LQDA Yearly Current Assets VS Current LiabilitesLQDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

LQDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.17%.
The Revenue for LQDA has decreased by -19.98% in the past year. This is quite bad
The Revenue has been growing by 11.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-39.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.52%
Revenue 1Y (TTM)-19.98%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%-35.62%

3.2 Future

The Earnings Per Share is expected to grow by 26.02% on average over the next years. This is a very strong growth
LQDA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.86% yearly.
EPS Next Y3.99%
EPS Next 2Y32.93%
EPS Next 3Y32.8%
EPS Next 5Y26.02%
Revenue Next Year174.73%
Revenue Next 2Y206.99%
Revenue Next 3Y157.08%
Revenue Next 5Y94.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LQDA Yearly Revenue VS EstimatesLQDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
LQDA Yearly EPS VS EstimatesLQDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LQDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LQDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LQDA Price Earnings VS Forward Price EarningsLQDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LQDA Per share dataLQDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

LQDA's earnings are expected to grow with 32.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.93%
EPS Next 3Y32.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LQDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIQUIDIA CORP

NASDAQ:LQDA (4/23/2025, 8:19:07 PM)

After market: 13.55 0 (0%)

13.55

+0.06 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19 2025-03-19/bmo
Earnings (Next)05-08 2025-05-08/amc
Inst Owners61.89%
Inst Owner Change0.22%
Ins Owners4.02%
Ins Owner Change2.71%
Market Cap1.16B
Analysts85
Price Target27.31 (101.55%)
Short Float %15.99%
Short Ratio12.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.39%
Min EPS beat(2)-20.44%
Max EPS beat(2)21.21%
EPS beat(4)1
Avg EPS beat(4)-17.98%
Min EPS beat(4)-66.65%
Max EPS beat(4)21.21%
EPS beat(8)1
Avg EPS beat(8)-35.22%
EPS beat(12)4
Avg EPS beat(12)-19.11%
EPS beat(16)6
Avg EPS beat(16)-20.24%
Revenue beat(2)1
Avg Revenue beat(2)-16.84%
Min Revenue beat(2)-37.8%
Max Revenue beat(2)4.12%
Revenue beat(4)1
Avg Revenue beat(4)-32.33%
Min Revenue beat(4)-62.04%
Max Revenue beat(4)4.12%
Revenue beat(8)3
Avg Revenue beat(8)-16.85%
Revenue beat(12)6
Avg Revenue beat(12)-7.37%
Revenue beat(16)10
Avg Revenue beat(16)16.8%
PT rev (1m)5.7%
PT rev (3m)5.84%
EPS NQ rev (1m)-5.72%
EPS NQ rev (3m)1.77%
EPS NY rev (1m)-8.11%
EPS NY rev (3m)-6.45%
Revenue NQ rev (1m)-14.59%
Revenue NQ rev (3m)-21.09%
Revenue NY rev (1m)-10.86%
Revenue NY rev (3m)-11.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 82.58
P/FCF N/A
P/OCF N/A
P/B 14.96
P/tB 16.46
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0.16
BVpS0.91
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.62%
ROE -168.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 384.57%
Cap/Sales 60.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.43
Quick Ratio 4.42
Altman-Z 0.2
F-Score2
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)306.37%
Cap/Depr(5y)189%
Cap/Sales(3y)42.88%
Cap/Sales(5y)46.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.52%
EPS Next Y3.99%
EPS Next 2Y32.93%
EPS Next 3Y32.8%
EPS Next 5Y26.02%
Revenue 1Y (TTM)-19.98%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%-35.62%
Revenue Next Year174.73%
Revenue Next 2Y206.99%
Revenue Next 3Y157.08%
Revenue Next 5Y94.86%
EBIT growth 1Y-65.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.77%
OCF growth 3YN/A
OCF growth 5YN/A